1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Seattle Genetics Inc (SGEN) Files 10-K for the Fiscal Year Ended on December 31, 2017

February 15, 2018 | About:

Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Seattle Genetics Inc is a development-stage biotech company. It develops monoclonal antibody-based therapies. Its lead product, Adcetris, has received approval for relapsed/refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma. Seattle Genetics Inc has a market cap of $7.81 billion; its shares were traded at around $54.06 with and P/S ratio of 17.01. Seattle Genetics Inc had annual average EBITDA growth of 1.20% over the past five years.

For the last quarter Seattle Genetics Inc reported a revenue of $129.6 million, compared with the revenue of $105.3 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $482.3 million, an increase of 15.3% from last year. For the last five years Seattle Genetics Inc had an average revenue growth rate of 17.4% a year.

The reported loss per diluted share was 88 cents for the year, compared with the loss per share of $0.51 in the previous year. The Seattle Genetics Inc had an operating margin of -40.6%, compared with the operating margin of -34.13% a year before. The 10-year historical median operating margin of Seattle Genetics Inc is -49.69%. The profitability rank of the company is 5 (out of 10).

At the current stock price of $54.06, Seattle Genetics Inc is traded at close to its historical median P/S valuation band of $59.15. The P/S ratio of the stock is 17.01, while the historical median P/S ratio is 18.60. The stock lost 14.03% during the past 12 months.

CEO Recent Trades:

  • President and CEO Clay B Siegall sold 18,832 shares of SGEN stock on 02/09/2018 at the average price of $49.75. The price of the stock has increased by 8.66% since.

Directors and Officers Recent Trades:

  • Director, 10% Owner Bros. Advisors Lp Baker bought 3,846,153 shares of SGEN stock on 02/01/2018 at the average price of $52. The price of the stock has increased by 3.96% since.

For the complete 20-year historical financial data of SGEN, click here.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by insider

User Generated Screeners

kislevamnontrial good pio desc 10
timjaegerPeter lynch screen
mjspencerhealthcare growth no debt
bdagrosaLong Stocks
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat